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Importance: Tumor Treating Fields (TTFields) are an anti-mitotic treatment approved
for treating newly diagnosed and recurrent glioblastoma, and mesothelioma. TTFields in
glioblastoma comprise alternating electric fields (200 kHz) delivered continuously, ideally
for ≥18 h/day, to the tumor bed via transducer arrays placed on the shaved scalp. When
applied locoregionally to the tumor bed and combined with systemic temozolomide
chemotherapy, TTFields improved overall survival vs. temozolomide alone in patients
with newly diagnosed glioblastoma. Improved efficacy outcomes with TTFields were
demonstrated, while maintaining a well-tolerated and manageable safety profile. The
most commonly-reported TTFields–associated adverse events (AEs) are beneath-array
dermatologic events. Since survival benefit from TTFields increases with duration-of-use,
prevention and management of skin AEs are critical to maximize adherence. This paper
describes TTFields-associated dermatological AEs and recommends prevention and
management strategies based on clinical trial evidence and real-world clinical experience.
Observations: TTFields–associated skin reactions include contact dermatitis
(irritant/allergic), hyperhidrosis, xerosis or pruritus, and more rarely, skin erosions/ulcers
and infections. Skin AEs may be prevented through skin-care and shifting (∼2 cm)
of array position during changes. TTFields–related skin AE management should be
based on clinical phenotype and severity. Depending on diagnosis, recommended
treatments include antibiotics, skin barrier films, moisturizers, topical corticosteroids,
and antiperspirants. Water-based lotions, soaps, foams, and solutions with minimal
impact on electrical impedance are preferred with TTFields use over petroleum-based
ointments, which increase impedance.
Conclusions: Early identification, prophylactic measures, and symptomatic skin AE
management help patients maximize TTFields usage, while maintaining quality-of-life and
optimizing therapeutic benefit.
Lacouture et al. Managing TTFields-Associated Skin Adverse Events
Implications for practice: TTFields confer a survival benefit in patients with
glioblastoma that correlates positively with duration of daily use. Skin events (rash) are
the primary treatment-related AE that can limit duration of use. The recommendations
described here will help healthcare professionals to recognize, prevent, and manage
dermatologic AEs associated with TTFields treatment. These recommendations may
improve cutaneous health and support adherence to therapy, both of which would
maximize treatment outcomes.
Keywords: glioblastoma, safety, skin management, Tumor Treating Fields, TTFields, Optune
INTRODUCTION
Glioblastoma
Glioblastoma (GBM) is the most common and aggressive
primary brain tumor (1). It is classified as a grade IV
tumor (2), and median survival ranges from 14.6 to 16.8
months with standard therapies (3–6). The 5-year survival
rate is estimated at 6.8% in the United States (US) (1), with
rates up to 9.8% reported in clinical trials (3). Treatment is
difficult because tumor margins are hard to visualize, resection
may damage vital brain functions (7), and the blood–brain
barrier limits entry of systemic therapies (8). In addition,
there is variation in the genetic and molecular features
of tumors, as well as a high degree of inter- and intra-
tumor heterogeneity (9). For these reasons, standard-of-care
therapy for GBM has been limited until recently, consisting
only of maximal surgical resection followed by radiotherapy
(60Gy in 2.0Gy fractions) plus concurrent temozolomide
(TMZ) chemotherapy (75 mg/m2 daily), followed by adjuvant
TMZ (150–200 mg/m2 on a 5-day schedule every 28 days)
(10). The most common adverse events (AEs) related to
concurrent radiotherapy and TMZ include fatigue (33%),
grade 3/4 hematologic toxic effects including neutropenia and
thrombocytopenia (7%), thromboembolic events (4%), and
severe infections (3%) (10). GBM treatment continues to
be challenging, since recurrence is almost inevitable despite
treatment (10, 11).
Tumor Treating Fields
Tumor Treating Fields (TTFields; Optune R©, Novocure Inc) are a
unique, non-invasive, antitumor treatment modality that delivers
low-intensity, alternating electric fields (200 kHz) locoregionally
to tumor beds in the brain, through 2 pairs of orthogonally
positioned transducer arrays affixed directly to the shaved scalp
of patients with GBM (Figure 1) (12, 13). Alternating electric
fields disrupt the rapid cell division of cancer cells and interfere
withmitotic spindle microtubule formations, ultimately resulting
in cancer cell death (12, 14). Additional mechanisms of action
against cancer cells include apoptosis induction (15), DNA
repair inhibition (16), DNA replication stress induction (17),
migration and invasion impairment, angiogenesis suppression
(18), autophagy upregulation (19), and immunogenic cell
death (20). Moreover, in preclinical studies, TTFields reversibly
increased tumor cell-specific membrane permeability (21) and
had a transient effect on blood–brain barrier integrity and
permeability, with the potential to deliver systemic therapies to
the brain (22).
Each TTFields transducer array is composed of 9
biocompatible insulated ceramic disks covered by hydrogel
on the skin-facing side and attached to a flexible adhesive
bandage on the opposite (external) side (Figure 1). Arrays are
supplied to patients in individual, presterilized packages to
minimize cross-contamination and infection risk. The arrays
are worn continuously for 3–4 days before removal for hygienic
scalp skin care and reshaving of the scalp to ensure array contact
with skin. Current standard practice during array changes is to
wipe the skin with 70% ethanol (not recommended on irritated
skin). Magnetic resonance imaging is used to guide the optimal
array layout for each patient based on tumor location and extent
(23). Each array has 8 temperature sensors (thermistors) that
continuously monitor temperature; if the array temperature
exceeds 41◦C (105.8◦F), the device will shut off and sound
an alarm (24). Patients should use the device for ≥18 h/day
on average, according to the EF-14 clinical trial design (6).
Notably, increased TTFields usage is independently prognostic
of improved survival in GBM, with a usage threshold of 50% and
a maximum effect on survival with >90% usage (25, 26).
TTFields in Clinical Practice
TTFields were approved for recurrent GBM in the European
Union (EU) in 2009, the US in 2011, Japan in 2015 (27, 28),
as well as recent approval in China in 2020 (with simultaneous
approval as adjuvant therapy in newly diagnosed GBM), followed
by approval in EU, US, and Japan as adjuvant therapy for newly
diagnosed GBM (28). In the US, TTFields are approved as
monotherapy for adult patients with recurrent supratentorial
GBM and in combination with standard-of-care chemotherapy
for newly diagnosed supratentorial GBM following surgery
and radiotherapy. National Comprehensive Cancer Network
(NCCN) guidelines recommend TTFields as a category 1
treatment in combination with TMZ after maximal safe resection
and completion of radiotherapy in patients with newly diagnosed
GBM (29), and the American Society of Clinical Oncology has
recognized TTFields as a treatment that has advanced clinical
cancer care (30).
Approvals were based on 2 pivotal, phase 3 clinical trials
comparing TTFields therapy with active standard chemotherapy
in patients with recurrent or newly diagnosed GBM (6, 31).
In the EF-11 trial, TTFields demonstrated comparable overall
survival (OS) to active chemotherapy in recurrent GBM, with
a median OS of 6.6 vs. 6.0 months, respectively (hazard ratio
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FIGURE 1 | The Tumor Treating Fields (TTFields) device and transducer arrays. Top left panel: second generation (Gen 2) battery-operated field generator device,
portable battery packs, plug-in power supply, tan transducer arrays, connection cables and box, and carrying case. This results in an increased operational efficiency
and improved patient experience. Top right panel: Shows a patient* with glioblastoma during therapy, wearing the tan transducer arrays on his scalp. Bottom
panels: 1. A hypoallergenic cover tape holds tan arrays in place on the scalp. 2. Transducer arrays deliver low intensity, intermediate frequency (200 kHz) alternating
electric fields and monitor the temperature of the scalp. 3. Conductive hydrogel layers (top) ensure separation between the arrays and skin, and the ceramic disks
(beneath) transmit TTFields without direct contact with the skin. 4. Mid-pads mechanically stabilize the gel over the arrays. 5. An overlapping liner covers the gel and
cover tape. 6. A cable connects array to the connection box. *Permission for global image use was obtained from the patient.
[HR] = 0.86; 95% CI, 0.66–1.12; P = 0.27), though failed to
demonstrate superiority, which was the primary objective (31).
However, in the EF-14 trial, addition of TTFields to TMZ for
newly diagnosed GBM resulted in a significantly improved
median OS of 20.9 vs. 16.0 months with TMZ alone (HR = 0.63;
95% CI, 0.53–0.76; P < 0.001) (6). Significant survival benefits
were reported irrespective of age, sex, performance status, and/or
extent of resection. Long-term follow-up showed 5-year OS with
TMZ alone was less than half that of TTFields plus TMZ (5 vs.
13%, respectively; P = 0.0037) (6).
In both phase 3 TTFields/GBM clinical trials (6, 31),
TTFields-related AEs were mostly grade 1/2 (mild-to-
moderate) in severity, manageable without substantial treatment
breaks, and resolved completely after treatment was stopped.
In the EF-11 trial of recurrent GBM, significantly more
gastrointestinal, hematologic, and infectious AEs were observed
with chemotherapy vs. TTFields (31). Moreover, the EF-14 trial
of newly diagnosed GBM showed no significant increase in
systemic AEs with TTFields when compared with TMZ alone (48
vs. 44%, respectively; P = 0.58) (6). Additionally, quality-of-life
analyses of the EF-14 trial found no significant differences
between treatment arms except for more itchy skin in TTFields-
treated patients (32). Notably, 75% of patients used TTFields for
the recommended ≥18 h/day, suggesting good tolerability (6).
Dermatologic conditions beneath the transducer arrays were
the most commonly reported TTFields-related AEs in all clinical
studies to date (33). In the EF-11 clinical trial, grade 1/2 skin AEs
occurred in 16% of patients; all were manageable and reversible,
with none resulting in discontinuation from the study (31).
In the EF-14 trial, grade 1/2 skin AEs beneath the transducer
arrays occurred in 52% of patients receiving TTFields plus
TMZ compared with none receiving TMZ monotherapy (6).
A retrospective analysis of real-world safety surveillance data
from 7,408 patients with GBM treated with TTFields since 2011
confirmed clinical trial findings. Skin reactions were the most
prevalent AE, occurring in 35% and 20% of patients with newly
diagnosed or recurrent GBM, respectively (34). Furthermore, the
post-marketing Patient Registry Dataset (PRiDe), including 457
patients with recurrent GBM treated with TTFields, reported a
similar pattern of AEs, with 24.3% of patients reporting skin
reactions beneath the transducer arrays, and 11.3% reporting
heat sensations (local heat beneath the arrays; described as a
warm sensation) (35). No new safety signals or unexpected
AEs were reported. Furthermore, these published phase 3
TTFields/GBM clinical trial data and prior registry observations
were consistent with findings from a recently published
retrospective, real-world, global post-marketing surveillance
analysis that evaluated safety of TTFields in patients with brain
cancer in the real-world, clinical practice setting (36). This
analysis reported on AEs from a large patient cohort who were
TTFields-treated (N = 11, 029; largest dataset to date) as well as
subgroups (region, diagnosis, and age). The majority of patients
were diagnosed with ndGBM and rGBM (n = 10, 232; one
of largest datasets of patients with GBM). Overall, TTFields
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treatment showed a favorable safety profile with no new safety
signals in the total cohort and across subgroups and suggested
feasibility in multiple subpopulations, including elderly patients.
The most commonly reported array-related AE was localized,
mild-to-moderate skin reactions and no treatment-related
systemic effects were noted. These data have further confirmed
the known safety and tolerability of TTFields for GBM.
In 2014, initial recommendations published on the
characterization, prevention, and management of TTFields-
associated dermatologic AEs concluded that prevention and
timely management are crucial to maintaining patient quality-
of-life, ensuring consistent use of TTFields, and ultimately
maximizing clinical benefit (24). Adoption of TTFields therapy
for GBM has subsequently increased considerably, allowing for
symptom-based characterization, prevention, and management
of dermatologic AEs associated with treatment in clinical
practice. The objectives of the current recommendations
are to better define the specific dermatologic AEs associated
with TTFields and to summarize prophylactic and practical,
treatment-based strategies for skin AE management based on
evidence from clinical trials and real-world clinical experience.
CHARACTERIZATION OF DERMATOLOGIC
ADVERSE EVENTS ASSOCIATED WITH
TTFIELDS
TTFields-associated dermatologic AEs result from distinctive
mechanical, thermal, chemical, and moisture-related stresses
related to prolonged contact with transducer arrays and adhesive,
which are applied sequentially to the same area of the skin
(24). Thermal injury is unlikely, as the device shuts off and an
alarm sounds if the array temperature exceeds 41◦C, which is
below the threshold for a thermal skin burn (24). Mechanical
trauma from shaving and/or constant array pressure and
reapplication may lead to epidermal loss with inflammation,
which may be complicated by skin infections, erosions, and
ulcerations, especially at the site of previous surgical scars.
Irritant contact dermatitis may result from chemical irritation
from the hydrogel or alcohol, and/or moisture (24). Predisposing
factors for patients with GBM include prior radiation in the area,
ongoing dexamethasone treatment, and combination treatment
with chemotherapy (cytotoxic alkylating agents, such as TMZ), or
targeted treatments (e.g., bevacizumab, an antiangiogenic agent,
or mammalian target of rapamycin [mTOR]/mitogen-activated
protein kinase [MEK] inhibitors). While bevacizumab is the only
targeted therapy currently indicated for recurrent GBM, NCCN
guidelines suggest compassionate use of other targeted therapies
in patients with recurrent GBM and relevant mutations (29).
Identification and Classification of
Dermatologic AEs
Five types of dermatologic AEs have been identified with
TTFields utilization, all of which are more likely to occur where
the scalp makes contact with adhesive or hydrogel on the
transducer arrays (Table 1) (24, 39).
1 Hyperhidrosis is excessive sweating of the scalp, which
can be caused by multiple factors, including climate,
physical activity, concomitant medications, and genetic
predisposition (Case 1).
2 Xerosis or pruritus (alone or in combination) is caused by
ambient humidity and temperature, concomitant medications,
genetic predisposition, and skin water loss (Case 2).
3 Contact dermatitis is inflammation of the skin caused by
irritant exposure. Exposure to chemical irritants elicits non-
specific release of local inflammatory chemokines (irritant
contact dermatitis), while exposure to exogenous allergens
induces specific immunologic response mechanisms based
on allergen sensitization (allergic contact dermatitis) (40).
Dermatitis can manifest as erythema, edema, pruritus, or
burning and scaling of the skin (Case 3).
4 Skin erosions are moist, circumscribed, depressed, secondary
lesions that result from loss of a portion or all of the viable
epidermis, but do not extend into the dermal layer (24).
Skin ulcers are secondary lesions involving the epidermal and
dermal layers, which may result in scarring (24). The base may
be clean, necrotic, or contain granulation tissue. They may
involve mild bleeding, pain, and/or burning (Case 4).
5 Skin and soft tissue infections are caused by damage to the
skin barrier, resulting in an abundance of pathogenic microbes
within the skin and supporting structures (37, 38). Pustules
may contain a hair at the center (folliculitis), vary in size, and
even coalesce (Case 5).
MANAGEMENT OF DERMATOLOGIC
ADVERSE EVENTS
Identification and Stratification of Risk
Factors
Multiple factors increase the risk of developing dermatologic
AEs in patients treated with TTFields (39). Prior craniotomies,
especially those that necessitated scalp reconstruction, may
increase risk (39, 41), and skin breakdown is more likely to
occur from transducer array placement over surgical scar lines
and surgical hardware from craniotomy repair. While surgical
hardware is not an absolute contraindication for TTFields
use, oncologists should consider this when planning array
placement, and oncology nurses should discuss array and
adhesive placement and avoidance of surgical hardware and scars
with patients and caregivers.
Patients with pre-existing skin conditions or who previously
developed contact dermatitis to any materials used on the arrays
(adhesive and hydrogel) are at increased risk (39). Patients with
hyperhidrosis (excessive sweating) have a higher complication
rate due to the hydrophilic nature of the hydrogel disks in the
arrays, which may liquefy upon exposure to sweat (39). Patients
with persistent alopecia, which is a sign of depletion of epidermal
stem cells in the follicular epidermis (42), may be more likely to
develop dermatitis, and patients with a history of skin exposure
to radiation (ultraviolet and/or ionizing) also have increased
risk. Pre-existing acute or chronic effects from radiation therapy,
such as dermatitis, scars, and fibrosis, may predispose the
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TABLE 1 | Dermatologic scalp adverse event (AE) types, symptomatology, potential causes, and treatment recommendations (24, 37–40).
Case 1: Tumor Treating Fields (TTFields) AE - hyperhidrosis
Symptomatology Potential Cause(s)





• Treat with aluminum chloride antiperspirant or topical glycopyrrolate at every array exchange
• Advise patients to avoid using ointments and medications that may cause sweating
• Consider referral to a dermatologist for botulinum toxin injections
Case 2: TTFields AE – pruritus
Symptomatology Potential Cause(s)
• Dry skin (xerosis)
• Itchy skin (pruritus)
• Flaky skin (dandruff)
• Genetic predisposition
• Cold/dry climate
• Loss of water/oil
• Medications
• May be related to contact dermatitis
Suggested Intervention(s)
• Advise patients to use fragrance-free or anti-dandruff shampoo
• Although part of the standard array change protocol, limit skin contact with alcohol-based products
• Topical corticosteroids may be prescribed if inflammation is present (e.g., betamethasone, clobetasol, fluocinonide)
• Identify cause and, if possible, reduce/eliminate
Case 3: TTFields AE – contact dermatitis
Symptomatology Potential Cause(s)
Contact
• Skin rash characterized by red, itching papules
• May resemble a burn
• Rash may present with red bumps that form moist, weeping
blisters
• Localized yet may be more diffuse than irritant type dermatitis
• Allergy to specific exogenous allergens, such as adhesive
tape and/or hydrogel, that come into contact with the skin





• Rash that may be itchy or painful
• Dermatitis restricted locally to the area of the irritant
• Non-specific inflammation caused by direct cellular damage
upon contact with an inherently harmful substance to cells
(e.g., chemical irritation from hydrogel, moisture, and/or
alcohol)
Suggested Intervention(s)
• Immediate removal of the irritant/allergen
• Transducer array removal from irritation/allergen site
• Topical corticosteroid (e.g., betamethasone, clobetasol, fluocinonide) application
• Apply a barrier film
• Consider trimming adhesive/surgilast if reaction exists to tape/adhesive
• If blistering develops, cold, moist compress application (20 min; 3 times/day) is recommended
• Consider systemic corticosteroids/treatment breaks if condition persists




• Breakdown of the outer epidermal layer of skin
• Skin discontinuity marked by incomplete loss of the epidermis
• May present as a delineated moist or depressed lesion
• Mild bleeding with pain or burning may be present
• Typically, erosions do not result in scarring
• Mechanical trauma from shaving and/or array application/
removal
• May develop from inflammation or maceration due to sweat,
rupture of vesicles, bullae from infection, or epidermal necrosis
(Continued)
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TABLE 1 | Continued
Ulcer
• Open scalp skin defects with potential for bleeding or oozing
• Complete loss of epidermis and portions of the dermis, fat, or
muscle, with increased risk of scarring
• Pustules may develop when infected
• Ischemic injury and/or decreased perfusion produced by array
pressure (especially in areas overlying scars, hardware, and
prior radiation exposure)
Suggested Intervention(s)
• Transducer array removal from site of erosion/ulcer – consider re-placement to avoid hardware exposure
• Wound dressing with gauzes, hydrogels, or hydrocolloids
• Assess wound and treat with topical antibiotic (e.g., clindamycin, gentamicin)
• Consider wound culture
• Keep clear of excess discharge and dead skin (severe cases may require surgical debridement)
• Return to clinic in 2 weeks; if condition persists, consider oral antibiotic/treatment break
Case 5: TTFields AE – dermatitis + infections
Symptomatology Potential Cause(s)
• Inflammation of skin or hair follicle (red pimple with hair in the
center)
• May have pus, itching, or burning
• Secondary bacterial infection
• Ultimately, infection with or without pustules may occur when
the skin is affected by pathogenic bacteria
Suggested Intervention(s)
• Assess wound and treat with topical antibiotic (e.g., clindamycin or gentamicin)
• Warm compresses with saltwater or Burow’s solution (5% aluminum subacetate)
• Take wound culture and potentially refer to dermatologist
• Return to clinic in 2 weeks; if condition persists, consider oral antibiotic/treatment break
scalp to injury from the arrays (41). Radiation injury may also
render skin less likely to recover from the subclinical alterations
related to array placement, continued contact, and removal.
Frequent array replacement beyond the recommended rate of
twice per week may damage the outer layer of the epidermis
by adhesive peeling and increased exposure of the dermis
to irritants.
Patients being treated with systemic anticancer agents such
as TMZ or bevacizumab, high doses of corticosteroids, or
oral antibiotics such as penicillin or cephalosporin are also
at increased risk of skin AEs (39). The anti-angiogenic
agent bevacizumab may increase the likelihood of wound
breakdown and delayed wound healing (41). Caution is therefore
required when combining TTFields and bevacizumab outside
a clinical trial. TMZ was found to cause neutropenia and
thrombocytopenia, which increase the probability of developing
secondary infections or severe bleeding, respectively (39). In
cancer patients treated with TMZ, the greater incidence of
high-risk AEs (e.g., hematological or gastrointestinal events)
may contribute to skin AE marginalization when weighing
treatment benefits against risks (e.g., treatment-related AEs) and
burden of disease. Yet, TMZ treatment alone has been associated
with skin AEs. In a recent phase 3 randomized trial, single-
arm TMZ treatment of patients with newly diagnosed GBM
demonstrated reported incidences of skin AEs that included
alopecia (16%), exanthema/rashes (14%), and erythema (3%), as
well as AE severity grades of 3 and 4 in some patients (∼2%)
(43). Hence, prudent monitoring of skin AEs and incorporating
preventative measures is important when TTFields is combined
with TMZ in patients with newly diagnosed GBM to best
support patient care, as TMZ may contribute to the onset
and/or exacerbation of skin AEs. Moreover, patients receiving
dexamethasone, which can lead to dry and thinning skin, may
also be more likely to develop skin AEs. Close monitoring is
thus recommended.
Before and after TTFields therapy initiation, healthcare
professionals should regularly examine and assess the scalp
to detect, manage, and thus prevent worsening of any
local skin irritation (44). Patients should have their scalp
assessed for xerosis, dermatitis, or hyperhidrotic skin and
treated accordingly prior to therapy initiation. The scalp
and shoulders should be assessed for xerosis and healthcare
professionals should advise patients to use fragrance-free
or anti-seborrheic dermatitis (dandruff) shampoo if present
and to avoid/limit skin contact with alcohol-based products.
Topical corticosteroid solutions or lotions may be prescribed
to reduce any inflammation present on the patient’s scalp.
Patients with grade 1 pruritus should be treated with
topical corticosteroids (e.g., betamethasone, clobetasol, or
fluocinonide), and oral gabapentin (100–600mg 3 times a
day as tolerated) or pregabalin (25–150mg twice daily as
tolerated; titrated up to 300mg twice daily if necessary) should
be considered for grade 2 pruritus. Hyperhidrosis may be
treated with topical aluminum chloride antiperspirant or topical
glycopyrrolate. In grade 2/3 cases, patients should be referred to
a dermatologist for consideration of either oral glycopyrrolate
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TABLE 2 | Prophylactic recommendations For patients treated with TTFields and caregivers (24, 39, 41, 45, 46).
Prophylactic intervention Recommendations For patients treated with TTFields and caregivers
Optimal shaving and preparation of the scalp to
maximize transducer-skin contact and minimize erosions
and other factors increasing the risk of infection
• Perform proper hand washing before preparing the scalp for array application
• Shave the scalp every time arrays are changed using gentle but firm circular motions – complete hair
removal is required for optimal adhesion
• Use a clean, electric razor to avoid cuts
• Mineral (baby) oil may be applied before shaving to allow for cleansing of the skin and facilitate removal
of bacteria and scale
Removal of natural oils and any moisture (sweat) from
the scalp prior to array placement
• Wash the scalp with mild, fragrance-free shampoo (e.g., baby shampoo) or dandruff shampoo
• If no skin irritation is present, wipe the scalp with a gauze or cotton ball soaked in first aid isopropyl
alcohol (70%)
• Ensure scalp is completely dry before array placement
Careful application and removal of transducer arrays is
crucial to decrease the risk of cutaneous irritation
• Change arrays at least every 3–4 days, or more frequently if they become wet or loosen (e.g., excessive
sweating during warmer weather or after intense physical activity)
• Apply mineral (baby) oil to the scalp to gently remove arrays; slowly and gently peel back the arrays
from the skin – pulling the skin or forceful rubbing of the scalp to remove adhesive can contribute to
skin breakdown and irritation so should be avoided
• Alternatively, the arrays may be removed in a hot shower by rubbing in a body wash containing coconut
oil causing them to slide off the scalp
• Evaluate the skin and scalp for signs of irritation with every array change, and notify your doctor or
nurse if there are signs of irritation (taking a picture of the affected area is advised)
Regular array repositioning to minimize direct pressure to
the scalp and ensure avoidance of surgical scar lines
• At each array change, shift array placement by ∼2 cm, ensuring that pairs of arrays are moved together
• Move arrays back to original position at subsequent change
• Avoid ceramic disc placement immediately over scars or surgical screws
• Wear breathable headwear to avoid overheating
or botulinum toxin injections. Increased skin health monitoring
is especially recommended for patients with the risk factors
described above.
Prophylactic Interventions
Early prophylactic interventions and good patient management
strategies, including optimal shaving and array repositioning,
may decrease the risk and severity of dermatologic AEs (Table 2;
Figure 2) (41, 46). Shifting array position by ∼2 cm when
reapplying is an important preventive measure and helps
minimize progression of current skin AEs (47). Arrays should be
shifted in pairs, allowing them to continue to work in tandem.
Ideally, arrays should be shifted back to their original position
to ensure optimal targeting of the tumor bed (13). Arrays
should be changed at least 2 times per week, approximately
every 3 days, although some patients may benefit from
more frequent replacement (e.g., with hyperhidrosis or quick
hair growth).
Patient and caregiver education is an essential part of
risk reduction, and oncology nurses play a critical role
in educating patients and caregivers on how to integrate
TTFields therapy into their daily life; this can subsequently
improve acceptance and adherence (45, 48–50). Nurses should
educate patients on what to expect at treatment initiation,
emphasizing the importance of communicating any changes in
skin condition to healthcare professionals as soon as possible.
Follow-up is important, particularly in the first 2 months after
treatment initiation. Awareness of prophylactic interventions
(including skin preparation, array placement and removal, and
monitoring for early signs of skin infection or inflammation)
is key for patient and caregiver education to reduce risk
of AEs (Table 2).
Pharmacologic Interventions and
Treatment Interruption
When dermatologic AEs develop, treatment decisions should
be based on the type and severity of symptoms in line with the
treatment algorithm (Figure 2). Additional recommendations
are outlined in Table 1. In general, the primary interventions
are topical corticosteroids (e.g., betamethasone, clobetasol,
or fluocinonide) for irritant or contact dermatitis and
topical antibiotics (e.g., clindamycin or gentamicin) for
skin ulcers/erosions or infections, applied at the time of array
changes and shifts (24, 39, 41). Instruct patients to apply a thin
layer to the dry scalp after array removal and cleaning, allowing
the agents to dry (24, 39, 45).
Topical agents (including antibiotics, corticosteroids,
antiseptics, skin barriers, cleansers, moisturizers, and
antiperspirants) are available in a variety of formulations
that may affect TTFields efficacy by altering electrical impedance
(51–53). In preclinical studies, water-based creams, gels, lotions,
soaps, foams, wipes/pads, sprays, and solutions had minimal
effects on electrical impedance (Figure 3A). Petroleum-based
ointments led to the highest increases in impedance and are thus
not recommended for use with TTFields. Products tested that
were found to have minimal impact on impedance are listed
in Figure 3B. Compatible treatments should be applied to the
scalp in a thin layer to prevent impedance effects and optimize
TTFields delivery.
Early detection of bacterial infections and appropriate
treatment with topical or oral antibiotics is critical. Obtaining
bacterial skin cultures prior to initiating antibiotic therapy is
recommended to identify the causative microorganism(s) and
ensure appropriate antimicrobial coverage (24). If uncertainty
between an inflammatory or infectious AE exists, consultation
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FIGURE 2 | Treatment algorithms for the prevention and management of dermatologic adverse events (AEs) associated with Tumor Treating Fields (TTFields)
application. GABA, gamma-aminobutyric acid; TMZ, temozolomide.
with a dermatologist is recommended in addition to empirical
therapy (41).
Treatment interruption may be required for intolerable grade
2 or worsening grade 3 dermatologic AEs (39). Interruption
of array application for 2–7 days in addition to topical
therapies is often sufficient for resolution of dermatologic AEs.
Prolonged interruption may compromise treatment efficacy (39).
Treatment interruption is also an option for recovery from a
skin AE that does not improve, despite treatment (41). Although
infrequent, skin ulcerations dictate array contact interruption
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FIGURE 3 | Effect of different skin care formulations on electrical impedance during Tumor Treating Fields (TTFields) application*. (A) Change in electrical impedance
following application of skin care agent. (B) Products tested with minimal effects on electrical impedance. *Data Provided by Moshe Giladi, PhD, Preclinical
Research, Novocure Ltd.
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until symptoms are grade 0/1 (45), which may require up to 14
days of treatment interruption.
Practical Management in the Clinic
In addition to the recommendations above, the following
practical advice based on clinical experience of TTFields-related
dermatologic AE management may be adopted:
Patient Visits
• Ask patients direct questions (e.g., “Do you sweat a lot?”; “Is
your scalp itchy?”).
• Patients are generally seen every 1–2 months for follow-up;
increase follow-up to 2-week intervals if dermatologic AEs
are present.
• Encourage patients to report any skin symptoms they
experience to a healthcare professional to ensure
timely management.
• Perform follow-up visits without transducer arrays on the
patient’s scalp to allow inspection of the skin. Array
replacement should thus be synchronized with follow-up visits
to minimize the frequency of array removal.
• If patients cannot be seen more frequently than every 2
months, 2-week follow-up can be performed remotely via
phone or telemedicine.
• If available, use electronic medical record (EMR) systems to
allow patients to send photos of their skin events to their
treating team.
• Visiting nurse services should be used where available,
especially in the absence of an array change partner
or caregiver.
Patient Education to Prevent Dermatologic AEs
• Encourage patients to identify a transducer array change
partner.
• Remind patients not to reuse the washcloth/towel that they use
on their body to wash/dry their scalp.
• Advise patients to shift the array positions∼2 cm (0.75 inches)
from the previous location when changing.
• For sensitive skin or hyperhidrosis, skin barrier products
(Figure 3B) are recommended to impedemoisture and protect
against dermatitis, irritants, and minor injury.
• To help reduce shearing forces to the skin when removing
arrays and adhesives, instruct patients to unplug the arrays and
remove slowly after wetting the arrays in the shower, and/or to
use adhesive removers (Figure 3B), mineral oils, or lubricating
soaps for easy removal.
• Educate patients to adhere to recommended AE skin
treatments to ensure continuous TTFields application.
• Emphasize the importance of avoiding placement of arrays
over hardware and/or surgical scars.
DISCUSSION
TTFields are a novel anticancer treatment for GBM that
involves placement of transducer arrays directly on the
scalp. Since treatment is locoregional, the safety profile
primarily includes local grade 1/2 dermatologic AEs beneath
the arrays. Although the toxicity profile of TTFields is more
favorable compared with most systemic therapies, treating
oncologists and support staff should become familiar with
the early identification and characterization of these unique
AEs. Training on TTFields-related dermatologic AE prevention
and management should be provided to all relevant staff,
including oncologists, nursing/support staff, and dermatologists.
In addition, training and education is required for patients and
caregivers to ensure that appropriate steps are taken to maintain
healthy skin and recognize when dermatologic events should be
discussed with a healthcare professional.
Patient or physician concerns regarding dermatologic AEs
should not be a barrier to starting or continuing TTFields
therapy, since these are the only treatment-related AEs and
are mild-to-moderate in severity in the vast majority of cases.
Continuity of treatment is highly correlated with TTFields
efficacy (26, 54). Physicians should thus consider referral to a
dermatologist in patients with challenging skin conditions rather
than discontinuing treatment. In addition, continuous use of
prophylactic measures, combined with early identification and
appropriate management of dermatologic AEs, can help patients
maximize TTFields treatment time (54). Use of appropriate
skin care strategies and medications to mitigate dermatologic
AEs, removal of arrays to check scalp, and proactive skin
AE prevention education, as well as balance of time on and
off therapy, will help minimize treatment interruptions and
maximize treatment adherence.
Management strategies for TTFields-associated dermatologic
AEs are likely to evolve as adoption of the therapy increases and
evidence from clinical trials and real-world settings accumulates;
such as the recent, aforementioned, global post-marketing
safety surveillance data from a large cohort (N=11,029) of
patients with GBM, high-grade gliomas, and other brain cancers
that provided real-world evidence that the safety profile of
TTFields in the clinical practice setting remains consistent with
published TTFields/GBM phase 3, clinical trial data (6, 31, 36).
Clinical trials with TTFields in other solid malignancies are
ongoing. TTFields (150 kHz) in combination with chemotherapy
was recently approved by the FDA for first-line treatment of
unresectable malignant pleural mesothelioma based on results
from the STELLAR trial (55). Dermatologic AEs were also the
main TTFields-related AE reported in that trial (68% in total,
with 66% as grade 1/2). Our clinical practice recommendations
may thus extend to patients with other malignancies receiving
TTFields. Future studies, such as the randomized, double-
blind PROTECT [NCT04469075] study (56), should help
establish which treatments can best reduce skin AEs in
patients with GBM.
CONCLUSIONS
The recommendations outlined here represent our current
understanding of the optimal prevention and management
of TTFields-related dermatologic AEs. Application of these
recommendations by healthcare professionals should help
patients to minimize dermatologic AEs, improve patient
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quality-of-life, support adherence to therapy, and potentially
improve treatment outcomes.
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